Codagenix Inc., a Long Island, New York-based developer of a software-based platform for vaccine design, raised $2M in Series A financing.
The investment was made by Topspin Fund of Roslyn NY.
The company intends to use the fund to expand its vaccine to new targets, and clinical testing of its ultra-low dose live-attenuated Influenza vaccine.
Co-founded by Steffen Mueller, President and Chief Scientific Officer, J. Robert Coleman, Chief Operating Officer, and Stony Brook, Codagenix is a pre-clinical biotechnology startup that develops live attenuated vaccines using a software-based rational design algorithm which re-structures viral genomes in a sub-optimal genetic code.
The company’s pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.